Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.

Related Keywords

Shanghai ,China ,Emory University ,Georgia ,United States ,Nabilf Saba ,Junshi Biosciences ,Coherus Biosciences ,Howard Halpern ,Shravan Kandula ,Neck Cancer Multidisciplinary Program ,Department Of Hematology ,Neck Cancer Research ,Medical Oncology ,Emory University School ,Howard Halpern Chair ,Winship Cancer Institute ,Adventhealth Medical Group Radiation Oncology ,Central Florida ,Shanghai Junshi ,Chenq Y ,Chend P ,Toripalimab ,Pd 1 Inhibitor ,Nasopharyngeal Carcinoma ,Phase 3 Jupiter 02 Trial Nct03581786 ,Phase 2 Polaris 02 Trial Nct02915432 ,